The diagnostic value of contrast enhancement on MRI in diffuse and anaplastic gliomas

Acta Neurochir (Wien). 2022 Aug;164(8):2035-2040. doi: 10.1007/s00701-021-05103-8. Epub 2022 Jan 11.

Abstract

Purpose: We evaluated differentiations in gadolinium contrast enhancement (CE) between low-grade WHO °II and high-grade WHO °III gliomas in conventional MRI, which have been repeatedly questioned.

Methods: Ninety-nine patients, who underwent first resection of WHO°II and °III gliomas, were retrospectively retrieved from a prospective database. The quantitative metric volume of Gd-CE in T1-weighted pre-operative MRI was measured using volumetric segmentation.

Results: The OR to detect CE in anaplastic gliomas was seven times higher than that in diffuse gliomas (CI95% 2.8-17.2, p<0.0001). No CE was seen in 50% (8/16) of focal anaplastic and in 28% (10/36) of entirely anaplastic gliomas. CE was present in 21% (10/47) of diffuse gliomas. Anaplasia correlated with a larger CE volume (r=0.49, p<0.0001) and provided additional 4 cm3 of CE volume compared to entirely diffuse tumors. The OR to have CE was 3.6 times for IDH1 wild-type tumors (CI95% 1.3-10.2, p=0.05) and 4.8 for tumors with ATRX expression (CI95% 1.3-17.2, p=0.05). In all sub-groups, at least a quarter of cases showed no CE at all and there were cases with present CE.

Conclusion: CE is associated with higher odds of unfavorable prognostic features like anaplasia, wild-type IDH1 and retained ATRX. There was no CE in one-fourth of anaplastic gliomas and half of gliomas with focal anaplasia.

Keywords: Anaplastic glioma; CE; Diffuse glioma; Lower-grade glioma; MRI.

MeSH terms

  • Anaplasia
  • Brain Neoplasms* / diagnostic imaging
  • Brain Neoplasms* / pathology
  • Brain Neoplasms* / surgery
  • Glioma* / pathology
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Magnetic Resonance Imaging
  • Mutation
  • Retrospective Studies

Substances

  • Isocitrate Dehydrogenase